SOMERSET, N.J., June 21, 2010 (GLOBE NEWSWIRE) -- inVentiv Health, Inc. (Nasdaq:VTIV) today announced that it has established a date for a special meeting of stockholders to consider and vote upon a proposal to adopt the previously announced merger agreement, dated May 6, 2010, providing for the acquisition of inVentiv Health, Inc. by Papillon Holdings, Inc., an entity created by certain affiliates of Thomas H. Lee Partners, L.P. inVentiv stockholders of record as of the close of business on June 15, 2010 will be entitled to notice of the special meeting and to vote at the special meeting. The special meeting will be held on Wednesday, July 21, 2010 at 9 a.m. EDT at 1180 Avenue of the Americas, 10th Floor (Times Square Conference Room), New York, NY. Shareholders also can attend the meeting via conference call. To listen, please dial 800-358-8448 (Domestic) or 706-634-1367 (International). The conference identification number is 83407790. In addition, the meeting will be webcast live on the Internet at http://www.inVentivHealth.com/health/newsroom/webcasts.asp . To participate, please go to the site at least 15 minutes in advance of the call to register, download and install any necessary audio software. About inVentiv Health inVentiv Health, Inc. (Nasdaq:VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com . The inVentiv Health, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4942 Additional Information and Where to Find It. A definitive proxy statement with the SEC concerning the previously announced proposed transaction contemplated by the Agreement and Plan of Merger, dated May 6, 2010, as amended, among the Company, Papillon Holdings, Inc. and Papillon Acquisition, Inc. was mailed on or about June 17, 2010 to stockholders of the Company. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the definitive proxy statement and other documents filed by the Company with the SEC at the SEC's Web site at www.sec.gov . The definitive proxy statement and such other documents will also be available for free on the Company's website at www.inventivhealth.com under Investor Relations or by directing such request to Investor Relations, inVentiv Health at 800-416-0555. The Company and its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed transaction. Information concerning the interests of the Company's participants in the solicitation is set forth in the Company's Annual Reports on Form 10-K for the year ended December 31, 2009, filed with the SEC on February 24, 2010, the Company's proxy statement for its 2010 annual meeting of stockholders, filed with the SEC on April 23, 2010, and in the definitive proxy statement relating to the proposed transaction.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
CONTACT: inVentiv Health, Inc. Investors/Corporate: David Bassin, CFO (732) 537-4804 firstname.lastname@example.org Media: Marcia Frederick (614) 543-6281 email@example.com